ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Ensysce Biosciences Inc

Ensysce Biosciences Inc (ENSC)

5.62
-0.50
(-8.17%)
Closed December 14 4:00PM
5.60
-0.02
(-0.36%)
After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
5.60
Bid
5.30
Ask
6.90
Volume
134,984
5.3401 Day's Range 6.3608
2.118 52 Week Range 30.90
Market Cap
Previous Close
6.12
Open
6.01
Last Trade Time
Financial Volume
$ 759,877
VWAP
5.6294
Average Volume (3m)
28,552,849
Shares Outstanding
19,574,014
Dividend Yield
-
PE Ratio
-24.70
Earnings Per Share (EPS)
-0.54
Revenue
2.23M
Net Profit
-10.63M

About Ensysce Biosciences Inc

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce's products are anticipated to provid... Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
New York, New York, USA
Founded
-
Ensysce Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENSC. The last closing price for Ensysce Biosciences was $6.12. Over the last year, Ensysce Biosciences shares have traded in a share price range of $ 2.118 to $ 30.90.

Ensysce Biosciences currently has 19,574,014 shares outstanding. The market capitalization of Ensysce Biosciences is $119.79 million. Ensysce Biosciences has a price to earnings ratio (PE ratio) of -24.70.

ENSC Latest News

Biotech Steals The Show Following $14 Million Grant Announcement

A California-based biotech company is finding a tremendous amount of success so far during Tuesday’s session after it was announced that the company received a $14 million To read the full...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.44-20.45454545457.048.68715.41375237.2533205CS
4-4.1245-42.41349169629.724511.13155.414567318.43417597CS
120.618512.41593897424.981514.672.118285528498.76808146CS
26-2.5105-30.95370199128.110514.672.118141666488.79521473CS
52-11.05-66.366366366416.6530.92.11875500159.39601946CS
156-15474.4-99.963824289415480252002.11834245791186.84336537CS
260-57378.4-99.990241182257384616322.11834812233067.71519745CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WKEYWISeKey International Holdings AG
$ 7.84
(139.02%)
75.53M
IPHAInnate Pharma SA
$ 3.00
(93.55%)
13.59M
AVLDirexion Daily AVGO Bull 2X Shares
$ 33.67
(48.92%)
658.55k
LOOPLoop Industries Inc
$ 1.8092
(47.09%)
82.56M
AVGXDefiance Daily Target 2X Long AVGO ETF
$ 31.49
(46.67%)
3.55M
RPTXRepare Therapeutics Inc
$ 1.765
(-55.54%)
4.7M
INOInovio Pharmaceuticals Inc New
$ 2.31
(-38.56%)
9.86M
XXII22nd Century Group Inc
$ 0.048
(-34.69%)
42.23M
FLGCFlora Growth Corporation
$ 1.30
(-34.34%)
4.14M
WTOUTime Limited
$ 0.281
(-32.74%)
3.79M
NVDANVIDIA Corporation
$ 134.25
(-2.25%)
231.23M
SOUNSoundHound AI Inc
$ 16.905
(23.66%)
159.56M
TRUGTruGolf Holdings Inc
$ 0.6794
(30.93%)
141.89M
RGTIRigetti Computing Inc
$ 7.155
(19.85%)
124.45M
AVGOBroadcom Inc
$ 224.80
(24.43%)
121.33M

ENSC Discussion

View Posts
BeeHaus2 BeeHaus2 5 days ago
Hey Glenn - when you send charts can you give sentiment? Good or Bad?
πŸ‘οΈ0
glenn1919 glenn1919 7 days ago
ENSC.....................https://stockcharts.com/h-sc/ui?s=ENSC&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
BeeHaus2 BeeHaus2 1 week ago
Interesting that this is holding up nicely after RS. I'm still bullish long term
πŸ‘οΈ0
BeeHaus2 BeeHaus2 2 weeks ago
And there it is. RS 1-15
https://ih.advfn.com/stock-market/NASDAQ/ensysce-biosciences-ENSC/stock-news/95028942/form-8-k-current-report
one-for-fifteen (1-for-15) reverse stock split (the β€œReverse Stock Split”) of our common stock, par value $0.0001 (the β€œCommon Stock”). The Reverse Stock Split will be effective as of 12:01 am on December 6, 2024 (the β€œEffective Time”).
πŸ‘οΈ0
BeeHaus2 BeeHaus2 3 weeks ago
RS coming. Not happy.

The stockholders approved an amendment to the Company’s Certificate of Incorporation to authorize the Company’s Board of Directors to combine outstanding shares of the Company’s common stock into a lesser number of outstanding shares, a β€œReverse Stock Split,” by a ratio of not less than one-for-ten and not more than one-for-forty, with the exact ratio to be set within this range by the Board in its sole discretion:
πŸ‘οΈ0
BeeHaus2 BeeHaus2 4 weeks ago
TIme to climb back up in line with the 5yr chart.
LFG!
πŸ‘οΈ0
Shift-4 Shift-4 4 weeks ago
ENSC profile via Zacks --> Yahoo:

https://finance.yahoo.com/news/ensc-improves-position-100000760.html

"We encourage investors to take a look at ENSC and consider the stock before the anticipated positive testing results come in."

-$
👍️ 1 🤑 1
glenn1919 glenn1919 1 month ago
ensc............................https://stockcharts.com/h-sc/ui?s=ensc&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Helter Skelter Helter Skelter 1 month ago
As of November 11, 2024, the registrant had 19,574,014 shares of common stock, $0.0001 par value per share, outstanding.

I'll get you an estimate on the float in a little bit...they turned a nice profit in the Q thanks to a gov grant...counted as revenue...

$ENSC
πŸ‘οΈ0
Shift-4 Shift-4 1 month ago
It’s nonsense. I’ll give it to the guy, he’s a good scalper and can hit tops on technical moves. But fundamentals…not so much.

There is no dilution because the warrants have been transferred (mostly from sabby) to a new owner who wants to convert them, but they are tied up until the shareholder meeting to vote on full conversion.

We’re seeing the effects of a chronically depressed market cap, bullish investors suddenly holding the warrants, and the loss of downward pressure due to the near-unlimited shorting collateral those warrants represented to Sabby. But dilution? Nope. There’s nothing available to dilute with.

-$
πŸ‘οΈ0
madras50 madras50 1 month ago
geez man you said that about WBUY and it nothing but go up.
πŸ‘οΈ0
BeeHaus2 BeeHaus2 1 month ago
Anyone know how many shares available, outstanding, float? I'm seeing conflicting info
πŸ‘οΈ0
glenn1919 glenn1919 1 month ago
ENSC..........................................https://stockcharts.com/h-sc/ui?s=ENSC&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
ENSC: Nice DD --- THANKS!!
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
Then try McDonald's new "E-Coli UN-Happy Meal" for breakfast, Homeboy!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 month ago
DILUTING THE SNOT OUT OF THIS...
πŸ‘οΈ0
tw0122 tw0122 1 month ago
Phase 3 late 2025...
Ensysce Biosciences submits Phase 3 study protocol for pain treatmentPublished 09/19/2024, 07:12 AM


Ensysce Biosciences submits Phase 3 study protocol for pain treatment


ENSC5.42%

SAN DIEGO - Ensysce Biosciences Inc. (NASDAQ:ENSC) has submitted a protocol for a Phase 3 clinical trial to the FDA, aiming to evaluate the efficacy and safety of its drug candidate PF614 for treating moderate to severe pain after abdominoplasty. The study will compare the analgesic efficacy of PF614 against a placebo and an active comparator at several clinical sites in the United States.
The trial, which is expected to yield results in late 2025, is part of the company's efforts to introduce PF614 as a potential improvement over existing oxycodone products. Ensysce's Chief Medical Officer, Dr. Bill Schmidt, expressed optimism that the trial will reinforce PF614's positive attributes. CEO Dr. Lynn Kirkpatrick highlighted the drug's extended duration, which could address the issue of breakthrough pain between doses, and its reduced potential for abuse.
Ensysce Biosciences focuses on developing prescription drugs with enhanced safety profiles, leveraging its proprietary Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms. The company aims to offer safer treatment options for severe pain and contribute to reducing medication abuse-related deaths.
The forward-looking statements in the original press release underscore the uncertainties inherent in the drug development process, including the possibility of encountering delays or failing to demonstrate safety and efficacy. The company acknowledges the risks and emphasizes that its product candidates are still in clinical stages and not yet approved for commercialization.
This news is based on a press release statement from Ensysce Biosciences.
In other recent news, Ensysce Biosciences has secured approximately $5 million from stock sales, managed by H.C. Wainwright & Co. The funds are anticipated to be allocated towards the continued development of its TAAP™ and MPAR® programs. Concurrently, the company has received a $14 million grant from the National Institutes of Health for the further development of its opioid product, PF614-MPAR. The funding will support the Phase 1b clinical trial of this opioid, designed to deter abuse and prevent overdose.
πŸ‘οΈ0
tw0122 tw0122 1 month ago
Loosing some sizzle from hot frying pan . Well done to medium rare
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
ENSC: Below is what "COPILOT" had to say about this right now, in the late Post-Market:

"Why is ENSC stock up 48% in the Post-Market today?
It looks like Ensysce Biosciences Inc. (ENSC) has seen a significant surge in their stock price due to a $5 million concurrent registered direct offering and exercise of warrants. This move has likely attracted investor interest, contributing to the 48% rise in the post-market."
πŸ‘οΈ0
Shift-4 Shift-4 1 month ago
Up 60% in AH to new highs due to recent 13G disclosing 9.9% investment (1.475m shares) by RA Capital.

Add this to the 1.3m from Perceptive Advisors on 10/29/24, and we've added 2.775m in institutional buys in the past 8 days.

Cost to borrow is obscene, and the market is *hot* right now. We could moon tomorrow.

-$
πŸ‘οΈ0
tw0122 tw0122 1 month ago
 14.4 million shares each with an exercise price of $0.47 per share, while up to 752,969 shares are issuable under the placement warrants, according to the filing.
πŸ‘οΈ0
Shift-4 Shift-4 1 month ago
They were paying me 385% at one point (not recently).

I'm here for the squeeze.

-$
πŸ‘οΈ0
BeeHaus2 BeeHaus2 1 month ago
Another solid day on good volume. Need to get through the .80s and test 1.00 next week.
πŸ‘οΈ0
glenn1919 glenn1919 1 month ago
ENSC............................................https://stockcharts.com/h-sc/ui?s=ENSC&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
INV4 INV4 1 month ago
ENSC looking good 😃

GLTA $ENSC
πŸ‘οΈ0
shrinknp shrinknp 1 month ago
The interest rate for ENSC loaned securities is 104%. Can someone explain to me the ludicrousness of this?
πŸ‘οΈ0
BeeHaus2 BeeHaus2 1 month ago
Time for the move above $1
👍️ 1 🚀 1
INV4 INV4 1 month ago
Bought some ENSC this morning!

$ENSC
πŸ‘οΈ0
madras50 madras50 1 month ago
somehow i doubt that
πŸ‘οΈ0
PirateLeviathan8 PirateLeviathan8 1 month ago
ENSC the next DRUG
πŸ‘οΈ0
PirateLeviathan8 PirateLeviathan8 1 month ago
ENSC go to the moon
πŸ‘οΈ0
glenn1919 glenn1919 1 month ago
ENSC...................................https://stockcharts.com/h-sc/ui?s=ENSC&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
BeeHaus2 BeeHaus2 1 month ago
A similar run here is possible.
πŸ‘οΈ0
tw0122 tw0122 1 month ago
.58 + 40%
πŸ‘οΈ0
bigrun bigrun 2 months ago
Hi, why is this ticker making big gains?
πŸ‘οΈ0
Shift-4 Shift-4 2 months ago
The hedge that bought 430k shares of DRUG two weeks ago on the day it started running from $3 to $108 within 4 days -- they just disclosed buying in for 1.3M shares at ENSC.

https://www.otcmarkets.com/filing/html?id=17924517&guid=CHL-kp-Ja1ZuB3h

-$
👍️ 1
BeeHaus2 BeeHaus2 2 months ago
Another nice move on heavy volume.
πŸ‘οΈ0
glenn1919 glenn1919 2 months ago
ENSC..........................https://stockcharts.com/h-sc/ui?s=ENSC&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
BooDog BooDog 2 months ago
After reading this from the company I'd think it's a matter of wheather or not Nasdaq will grant another 180 days after meeting their equity requirement. Possibly why this gapped up the other day.

What is the latest update from the Company in terms of Nasdaq listing requirements?

As of September 30, 2024, we believe we are in compliance with Nasdaq requirements regarding stockholders' equity and we are looking forward to the upcoming hearing with Nasdaq to discuss our plans to continue to maintain compliance with both the stockholders' equity requirement and the $1.00 bid price requirement.
https://finance.yahoo.com/news/ensysce-biosciences-provides-shareholder-responds-120000514.html

SAN DIEGO, CA / ACCESSWIRE / September 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has received notice from the listing qualifications department staff of The Nasdaq Stock Market ("Nasdaq") stating that the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company's common stock has remained below $1.00 per share through the initial 180-day compliance period ended September 23, 2024. The Company is not eligible for a second 180-day period because it does not comply with the minimum stockholders' equity requirement for initial listing on The Nasdaq Capital Market. The Nasdaq Hearings Panel will consider this matter in rendering a determination regarding the Company's continued listing on The Nasdaq Capital Market at an upcoming hearing which will also consider the Company's non-compliance with the $2.5 million stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1).
https://www.accesswire.com/924643/ensysce-biosciences-receives-notice-from-nasdaq

This caught my eye this morning with the PM volume.
πŸ‘οΈ0
frankyahoo frankyahoo 2 months ago
Today's volume was amazing. They came for it. Not sure it will be a multi day move but today was a good day.
πŸ‘οΈ0
Mr. Zen Mr. Zen 2 months ago
thanks, I'll take that as a compliment.
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 months ago
new highs on massive volume
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 months ago
THAT VOLUME
πŸ‘οΈ0
Invest-in-America Invest-in-America 2 months ago
ENSC: Below is COPILOT's answer just now to my question about ENSC.
https://copilot.microsoft.com/?FORM=hpcodx&showconv=1
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 months ago
so easy even a caveman can do it
πŸ‘οΈ0
Invest-in-America Invest-in-America 2 months ago
ENSC: "DILUTION HITTING HARD"??? (Heck, looks more like PROFITS HITTING HARD, for anybody in here.)
πŸ‘οΈ0
Mr. Zen Mr. Zen 2 months ago
Top gainer, here we go (eom)
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 months ago
.444
πŸ‘οΈ0
tw0122 tw0122 2 months ago
.47 Hey always the next one.. The A-3 warrants and A-4 warrants cover up to 14.4 million shares each with an exercise price of $0.47 per share, while up to 752,969 shares are issuable under the placement warrants, according to the filing.

The exercise of the warrants is conditional on shareholders' approval, the company added.

Ensysce said it will not receive any proceeds from the sale of shares by selling stockholders but will get proceeds from the exercise of warrants that will be used for working capital for general corporate purposes.

Shares of the company rose 2.8% in after-hours
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 months ago
shoulda coulda bought more

https://x.com/READY_2_PROFIT/status/1848687064797061273
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock